Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Medicenna Therapeutics Corp. MDNA NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CA • USD

SharesGrow Score
61/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Medicenna Therapeutics Corp. (MDNA) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.

MDNA Analyst Ratings

Buy
2
Ratings
2 Buy
Based on 2 analysts giving stock ratings to Medicenna Therapeutics Corp. in the past 3 months
Rating breakdown
Buy
2 100%
100%
Buy
2 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 OVID
OVID
Ovid Therapeutics Inc.
$2.76
-6.76%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.91
-0.02%
 CKPT
CKPT
Checkpoint Therapeutics, Inc.
$4.26
+0.00%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 SRZN
SRZN
Surrozen, Inc.
$32.02
+0.53%
 IVVD
IVVD
Invivyd, Inc.
$1.71
+6.21%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message